This held true in the Phase III NOVA trial (Mirza et al, 2016), in which patients with platinum‐sensitive recurrent ovarian cancer receiving niraparib (a PARPi) maintenance therapy had increased progression‐free survival (PFS) compared to placebo control, irrespective of BRCA1/2 mutational or HR deficiency status. The gene discussed is BRCA1; the disease is ovarian cancer.